MX2021007709A - Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular. - Google Patents
Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular.Info
- Publication number
- MX2021007709A MX2021007709A MX2021007709A MX2021007709A MX2021007709A MX 2021007709 A MX2021007709 A MX 2021007709A MX 2021007709 A MX2021007709 A MX 2021007709A MX 2021007709 A MX2021007709 A MX 2021007709A MX 2021007709 A MX2021007709 A MX 2021007709A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- pharmaceutical compositions
- ocular surface
- surface disease
- treating ocular
- Prior art date
Links
- 208000023715 Ocular surface disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 abstract 1
- 229960002537 betamethasone Drugs 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 230000001861 immunosuppressant effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 abstract 1
- 229960000951 mycophenolic acid Drugs 0.000 abstract 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785312P | 2018-12-27 | 2018-12-27 | |
| PCT/US2019/064371 WO2020139525A1 (en) | 2018-12-27 | 2019-12-04 | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007709A true MX2021007709A (es) | 2021-12-15 |
Family
ID=71127864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007709A MX2021007709A (es) | 2018-12-27 | 2019-12-04 | Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12070442B2 (https=) |
| EP (1) | EP3902525A4 (https=) |
| JP (1) | JP2022516099A (https=) |
| KR (1) | KR20210141448A (https=) |
| CN (1) | CN113473970A (https=) |
| AU (1) | AU2019417161B2 (https=) |
| BR (1) | BR112021012492A2 (https=) |
| CA (1) | CA3124945A1 (https=) |
| IL (1) | IL284344A (https=) |
| MX (1) | MX2021007709A (https=) |
| SG (1) | SG11202106967QA (https=) |
| WO (1) | WO2020139525A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7138103B2 (ja) | 2016-11-29 | 2022-09-15 | オキュリス エスエー | 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造 |
| WO2019060696A1 (en) * | 2017-09-25 | 2019-03-28 | Surface Pharmaceuticals, Inc. | OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE |
| WO2022076398A1 (en) * | 2020-10-07 | 2022-04-14 | Surface Ophthalmics, Inc. | Pharmaceutical kits and their use for treating dry eye disease |
| CA3124945A1 (en) | 2018-12-27 | 2020-07-02 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| EP4670738A3 (en) | 2019-07-01 | 2026-03-04 | Oculis Operations Sàrl | Method for stabilizing the ph of an aqueous composition comprising a drug |
| US12440510B2 (en) | 2021-05-10 | 2025-10-14 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| US12310981B2 (en) | 2021-05-10 | 2025-05-27 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| EP4469059A4 (en) * | 2022-01-24 | 2026-01-21 | Surface Ophthalmics Inc | PHARMACEUTICAL COMPOSITIONS OF MYCOPHENOLIC ACID AND/OR BETAMETHASONE FOR THE TREATMENT OF EYE DISORDERS |
| JP2025538061A (ja) | 2022-11-04 | 2025-11-26 | クラリス バイオ インコーポレイテッド | クロマカリムの局所眼内送達 |
| EP4616843A1 (en) * | 2024-03-13 | 2025-09-17 | Iakov Mirkin | Pharmaceutical composition for use in the treatment of ulcerative colitis and in the treatment of interstitial cystitis/bladder pain syndrome |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2503563A1 (fr) | 1981-04-09 | 1982-10-15 | Pos Lab | Composition pour collyre a base de sulfate de chondroitine a |
| US4863907A (en) | 1984-06-29 | 1989-09-05 | Seikagaku Kogyo Co., Ltd. | Crosslinked glycosaminoglycans and their use |
| US4696917A (en) | 1985-08-01 | 1987-09-29 | Lindstrom Richard L | Irrigation solution |
| CA2041828A1 (en) | 1990-03-05 | 1992-11-04 | Richard L. Lindstrom | Viscoelastic solution |
| US5514686A (en) | 1991-04-26 | 1996-05-07 | Fujisawa Pharmaceutical Co., Ltd. | Use of macrolide compounds for eye diseases |
| US5518732A (en) | 1995-02-14 | 1996-05-21 | Chiron Vision, Inc. | Bio-erodible ophthalmic shield |
| US7063857B1 (en) | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
| AU777915B2 (en) | 1999-04-30 | 2004-11-04 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
| US6489335B2 (en) | 2000-02-18 | 2002-12-03 | Gholam A. Peyman | Treatment of ocular disease |
| EP1142566B1 (fr) * | 2000-04-07 | 2003-10-01 | Laboratoire Medidom S.A. | Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate |
| CN1127955C (zh) | 2000-07-07 | 2003-11-19 | 中山医科大学中山眼科中心 | 一种眼前段及眼表免疫相关性疾病治疗药物 |
| DE10045343B4 (de) | 2000-09-14 | 2005-05-12 | Neuhann, Tobias, Dr.med. | Verwendung einer wässrigen Lösung oder Suspension zum Heilen des Hornhautepithels |
| AU2002230504A1 (en) | 2000-12-20 | 2002-07-01 | Alcon Universal Ltd. | Ophthalmic irrigating solution adapted for use in lasik surgery |
| US7087237B2 (en) | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
| US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
| EP1706095B1 (en) | 2004-01-20 | 2008-12-24 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| GB0404693D0 (en) | 2004-03-02 | 2004-04-07 | Univ London | Pharmaceutical preparations for the treatment of ocular surface and other disorders |
| WO2006044155A2 (en) | 2004-10-01 | 2006-04-27 | Lindstrom Richard L | Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same |
| EP1814518A1 (en) | 2004-11-23 | 2007-08-08 | Alcon Inc. | Triple natural polymer viscoelastic composition |
| US20060148686A1 (en) * | 2004-12-30 | 2006-07-06 | Bausch & Lomb Incorporated | Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy |
| US20070082841A1 (en) | 2005-09-27 | 2007-04-12 | Aciont, Inc. | Ocular administration of immunosuppressive agents |
| DE102005055275A1 (de) | 2005-11-17 | 2007-05-24 | Ursapharm Arzneimittel Gmbh & Co. Kg | Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung |
| WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| WO2007130364A2 (en) | 2006-05-01 | 2007-11-15 | Riolan Technologies, Inc. | Compositions, methods, and kits for treating dry eye |
| US20080242646A1 (en) | 2007-03-26 | 2008-10-02 | Lessem Jan N | Split dose corticosteroid therapy |
| JP5202986B2 (ja) | 2007-09-14 | 2013-06-05 | ロート製薬株式会社 | コンタクトレンズ装着液 |
| WO2009035033A1 (ja) | 2007-09-14 | 2009-03-19 | Rohto Pharmaceutical Co., Ltd. | 眼科用組成物 |
| JP2011505409A (ja) | 2007-12-04 | 2011-02-24 | ノバガリ ファーマ エスエー | パルミチン酸デキサメタゾンのようなコルチコステロイドプロドラッグを含有する眼障害の治療用の組成物 |
| US20100010082A1 (en) | 2008-07-09 | 2010-01-14 | Aspreva International Ltd. | Formulations for treating eye disorders |
| US10201548B2 (en) | 2009-03-06 | 2019-02-12 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
| US10980818B2 (en) | 2009-03-06 | 2021-04-20 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
| JP5595206B2 (ja) | 2009-09-30 | 2014-09-24 | ロート製薬株式会社 | 眼科用液体組成物 |
| EP2308468A1 (en) | 2009-10-08 | 2011-04-13 | Novaliq GmbH | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
| US20120264852A1 (en) | 2009-10-29 | 2012-10-18 | Colorado State University Research Foundation | Polymeric materials including a glycosaminoglycan networked with a polyolefin-containing polymer |
| FR2962044B1 (fr) | 2010-04-21 | 2013-02-22 | Horus Pharma | Emulsion lacrymimetique |
| US9233123B1 (en) | 2010-12-07 | 2016-01-12 | Richard L. Lindstrom | Use of ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan |
| JP5925188B2 (ja) | 2011-04-08 | 2016-05-25 | ナノシータ株式会社 | 医薬製剤 |
| DK2797601T3 (en) * | 2012-02-10 | 2018-06-14 | Taiwan Liposome Co Ltd | PHARMACEUTICAL COMPOSITIONS FOR REDUCING COMPLICATIONS BY Ocular steroid |
| US9549966B2 (en) | 2012-02-21 | 2017-01-24 | Massachusetts Eye & Ear Infirmary | Inflammatory eye disorders |
| ITPD20120098A1 (it) | 2012-03-30 | 2013-10-01 | Fidia Farmaceutici | "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico" |
| ITMI20120896A1 (it) | 2012-05-23 | 2013-11-24 | Bongulielmi Reto | Condroitina per uso in medicina |
| JP6452283B2 (ja) | 2012-11-06 | 2019-01-16 | ロート製薬株式会社 | 眼の異物感改善剤 |
| EP2916827B1 (en) * | 2012-11-08 | 2020-06-10 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
| EP2937088B1 (en) | 2012-12-21 | 2020-11-18 | Tokushima University | Composition having tissue repairing activity and utilization thereof |
| WO2015005458A1 (ja) | 2013-07-10 | 2015-01-15 | 生化学工業株式会社 | グリコサミノグリカン誘導体及びその製造方法 |
| US20150100348A1 (en) | 2013-10-08 | 2015-04-09 | Ims Health Incorporated | Secure Method for Health Record Transmission to Emergency Service Personnel |
| EP2979689A1 (en) | 2014-07-29 | 2016-02-03 | Sygene Technologies | Composition for an eye drop and delivery system therefor |
| JP2016050181A (ja) * | 2014-08-29 | 2016-04-11 | 大日本住友製薬株式会社 | 血管炎治療剤 |
| ES2938482T3 (es) | 2015-01-16 | 2023-04-11 | Seikagaku Kogyo Co Ltd | Sulfato de condroitina reticulado, composición que contiene el mismo y agente de tratamiento para enfermedad ocular |
| TWI773641B (zh) | 2015-05-08 | 2022-08-11 | 日商活效製藥股份有限公司 | 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑 |
| US9789080B2 (en) * | 2015-09-04 | 2017-10-17 | Insite Vision Incorporated | Ophthalmic formulations of mycophenolic acid |
| US20190008891A1 (en) | 2016-01-29 | 2019-01-10 | Seikagaku Corporation | Stabilized aqueous composition comprising chondroitin sulfate and hyaluronic acid |
| JP7288289B2 (ja) | 2016-11-11 | 2023-06-07 | ロート製薬株式会社 | 水性眼科組成物 |
| KR20190095937A (ko) | 2016-12-11 | 2019-08-16 | 시너지 더마톨로지 리미티드 | 설페이트화된 다당류를 포함하는 조성물 |
| EP3558308A1 (en) | 2016-12-22 | 2019-10-30 | Novaliq GmbH | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases |
| US20190008920A1 (en) | 2017-05-19 | 2019-01-10 | Ocugen, Inc. | Ophthalmic compositions and methods of use |
| EP3624773A4 (en) * | 2017-05-19 | 2021-04-07 | Ocugen, Inc. | OPHTHALMIC COMPOSITIONS AND METHOD OF USE |
| US20220143075A1 (en) | 2017-09-25 | 2022-05-12 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| WO2019060696A1 (en) * | 2017-09-25 | 2019-03-28 | Surface Pharmaceuticals, Inc. | OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE |
| US20230277557A1 (en) | 2017-09-25 | 2023-09-07 | Surface Ophthalmics, Inc. | Pharmaceutical kits and their use for treating dry eye disease |
| JP7104553B2 (ja) | 2018-03-30 | 2022-07-21 | ロート製薬株式会社 | 眼科組成物 |
| JP7417365B2 (ja) | 2018-05-09 | 2024-01-18 | ロート製薬株式会社 | 水性眼科組成物 |
| TW202547536A (zh) | 2018-05-09 | 2025-12-16 | 日商樂敦製藥股份有限公司 | 眼科組成物 |
| CN113329754A (zh) | 2018-11-20 | 2021-08-31 | 麻雀制药股份有限公司 | 用于施用皮质类固醇的方法 |
| CA3124945A1 (en) | 2018-12-27 | 2020-07-02 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| JP6866412B2 (ja) | 2019-02-28 | 2021-04-28 | 株式会社伊勢半 | 油中水型乳化化粧料 |
| JP7758466B2 (ja) | 2019-11-07 | 2025-10-22 | ロート製薬株式会社 | 眼科組成物 |
| US20230061058A1 (en) | 2020-02-14 | 2023-03-02 | Industry-Academic Cooperation Foundation, Yonsei University | Hydrogel of chondroitin sulfate functionalized with phenol derivative and use thereof |
| JP2022157707A (ja) | 2021-03-31 | 2022-10-14 | ロート製薬株式会社 | 眼科組成物 |
| WO2022240589A1 (en) | 2021-05-12 | 2022-11-17 | Schlumberger Technology Corporation | Autonomous inflow control device system and method |
| EP4469059A4 (en) | 2022-01-24 | 2026-01-21 | Surface Ophthalmics Inc | PHARMACEUTICAL COMPOSITIONS OF MYCOPHENOLIC ACID AND/OR BETAMETHASONE FOR THE TREATMENT OF EYE DISORDERS |
-
2019
- 2019-12-04 CA CA3124945A patent/CA3124945A1/en active Pending
- 2019-12-04 US US17/418,813 patent/US12070442B2/en active Active
- 2019-12-04 SG SG11202106967QA patent/SG11202106967QA/en unknown
- 2019-12-04 WO PCT/US2019/064371 patent/WO2020139525A1/en not_active Ceased
- 2019-12-04 EP EP19902055.3A patent/EP3902525A4/en active Pending
- 2019-12-04 AU AU2019417161A patent/AU2019417161B2/en not_active Ceased
- 2019-12-04 BR BR112021012492-6A patent/BR112021012492A2/pt not_active Application Discontinuation
- 2019-12-04 KR KR1020217023758A patent/KR20210141448A/ko not_active Withdrawn
- 2019-12-04 CN CN201980092852.9A patent/CN113473970A/zh active Pending
- 2019-12-04 MX MX2021007709A patent/MX2021007709A/es unknown
- 2019-12-04 JP JP2021537848A patent/JP2022516099A/ja active Pending
-
2021
- 2021-06-24 IL IL284344A patent/IL284344A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210141448A (ko) | 2021-11-23 |
| AU2019417161A1 (en) | 2021-07-15 |
| EP3902525A4 (en) | 2022-09-28 |
| EP3902525A1 (en) | 2021-11-03 |
| BR112021012492A2 (pt) | 2021-09-08 |
| SG11202106967QA (en) | 2021-07-29 |
| CN113473970A (zh) | 2021-10-01 |
| AU2019417161B2 (en) | 2023-06-15 |
| WO2020139525A1 (en) | 2020-07-02 |
| CA3124945A1 (en) | 2020-07-02 |
| JP2022516099A (ja) | 2022-02-24 |
| US20220071945A1 (en) | 2022-03-10 |
| US12070442B2 (en) | 2024-08-27 |
| IL284344A (en) | 2021-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007709A (es) | Composiciones farmacéuticas oftálmicas y procedimientos para el tratamiento de las enfermedades de la superficie ocular. | |
| MX2018002723A (es) | Macrociclicos peptidomimeticos y usos de los mismos. | |
| AU2018338608A1 (en) | Methods, compositions, and implantable elements comprising active cells | |
| PH12022550167A1 (en) | High concentration anti-c5 formulations | |
| PH12021550621A1 (en) | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness | |
| HK1250940A1 (zh) | 用於预防上皮细胞的增殖和上皮-间充质转换的组合物和方法 | |
| WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| WO2019209962A8 (en) | Compounds and uses thereof | |
| PH12019500208A1 (en) | Spiro-lactam nmda receptor modulators and methods of using same | |
| MY196448A (en) | Anti-Htra1 Antibodies and Methods of use Thereof | |
| EP4596543A3 (en) | Farnesoid x receptor agonists and uses thereof | |
| WO2019209948A8 (en) | Compounds and uses thereof | |
| MX2021011723A (es) | Ligandos de pseudocinasa tyk2. | |
| MX2017015879A (es) | Composiciones de hidroxipropil beta-ciclodextrina y metodos. | |
| EP4454704A3 (en) | Methods for increasing sepiapterin plasma exposure | |
| PH12019501945B1 (en) | Composition and method for preventing or delaying onset of myopia comprising atropine | |
| MX2022000712A (es) | Moduladores de nlrp3. | |
| EA033345B1 (ru) | ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ | |
| MX2021004755A (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. | |
| EP4410312A3 (en) | Topical cyclosporine-containing formulations and uses thereof | |
| MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
| AU2017248276A1 (en) | Methods of treating ocular conditions | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| WO2019087130A3 (en) | Method of inhibiting angiogenesis |